Cytomegalovirus in renal transplantation

Journal of the American Society of Nephrology

Volumn 12, Issue 4, 2001, Pages 848-855

  Brennan, D C ^a  

^a BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA 1 ANTITRYPSIN; ALPHA1 PDX; CIDOFOVIR; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; LYMPHOCYTE ANTIBODY; PROBENECID; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR;

ATHEROSCLEROSIS; BIOASSAY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA RNA HYBRIDIZATION; DRUG EFFICACY; GLOMERULOPATHY; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH CARE COST; HERPES VIRUS INFECTION; HISTOPATHOLOGY; HISTORY; HUMAN; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NEUTROPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SERODIAGNOSIS; SURVIVAL; VIROLOGY; VIRUS CULTURE;

EID: 0035084616     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Propagation in tissue cultures of cytopathogenic virus from human salivary gland virus (SGV) disease
2. Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease
3. Cytomegalovirus as a possible cause of a disease resembling infectious mononucleosis
4. Cytomegaloviruses
5. Productive cytomegalovirus (CMV) infection exclusively in CD13-positive peripheral blood mononuclear cells from CMV-infected individuals: Implications for prevention of CMV transmission
6. Furin, a subtilisin/Kex2p-like pro-protein convertase
7. A protein-based therapeutic for human cytomegalovirus infection
8. Immediate early gene 2 of human cytomegalovirus increases interleukin 2 receptor-α gene expression
9. Cytomegalovirus immediate early genes prevent the inhibitory effect of cyclosporin A on interleukin 2 gene transcription
10. Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment
11. Viral strategies of immune evasion
12. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40
13. Human cytomegalovirus harbors its own unique Il-10 homolog (CMVIL-10)
14. Infectious complications in renal transplantation
15. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients
16. The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: Implications for organ allocation
17. Impact of cytomegalovirus serology on graft survival in living related kidney transplantation: Implications for donor selection
18. Peripheral T cell activation in long-term renal transplant patients: Concordant upregulation of adhesion molecules and cytokine gene transcription
19. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy
20. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis
21. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration
22. Human cytomegalovirus increases modified low density lipoprotein uptake and scavenger receptor mRNA expression in vascular smooth muscle cells
23. Does cytomegalovirus cause glomerular injury in renal allograft recipients?
24. Cyclosporine as cause of thrombotic microangiopathy after renal transplantation
25. Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: A new treatment strategy
26. Transplant-associated thrombotic microangiopathy: The role of IgG administration as initial therapy
27. CMV infection is associated with transplant renal artery stenosis
28. Viral infections in immunocompromised patients
29. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy
30. Effects of storage temperature and time on qualitative and quantitative detection of cytomegalovirus in blood specimens by shell vial culture and PCR
31. Correlation of cytomegalovirus DNA levels with response to antiviral therapy in cardiac and renal allograft recipients
32. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients
33. Ganciclovir
34. Are varicella zoster and herpes simplex sentinel lesions for cytomegalovirus in renal transplant recipients?
35. Cytomegalovirus hyperimmune globulin for CMV disease refractory to ganciclovir in renal transplantation
36. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients. A report from the European Group for Blood and Marrow Transplantation (EBMT)
37. Prevention of cytomegalovirus disease
38. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: A randomized controlled trial
39. Use of cytomegalovirus immune-globulin to prevent cytomegalovirus disease in renal-transplant recipients
40. The effect of polyimmune gammaglobulin for prophylaxis against reactivation cytomegalovirus infection in kidney and kidney/pancreas transplant recipient
41. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients: A meta-analysis
42. Intravenous immunoglobulin suppression of HLA alloantibody in highly-sensitized transplant candidates and transplantation with a histoincompatible organ
43. Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates
44. High-dose intravenous immune globulin and acute renal failure
45. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts
46. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients
47. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation
48. Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients
49. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients
50. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients
51. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group
52. Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations
53. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. The International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group
54. Valganciclovir provides ganciclovir plasma exposure similar to IV ganciclovir in transplant recipients
55. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial
56. Vaccines for the prevention of human cytomegalovirus infection
57. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients
58. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients
59. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation
60. Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient
61. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation
62. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function
63. Treatment of ganciclovir-resistant human cytomegalovirus infection